Fresh analysis reveals that patients who come off new GLP-1 drugs like Wegovy and Mounjaro can put back on lost weight far faster than those who end traditional lifestyle programs.
Findings released in a prominent health publication points out that while obese individuals often shed a large proportion of their total mass while undergoing treatment, the weight is regained at an estimated rate of nearly a kilo each month after stopping.
"People buying such medications need to be cognizant of the potential of rapid rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery means a return to starting mass within about a year and a half.
Weighing Therapies
The analysis, which examined 37 of studies involving thousands of patients, contrasted the effects of GLP-1 agonists with conventional dieting.
Researchers note that people who shed pounds through lifestyle changes alone generally have a more gradual weight regain—approximately 0.1 kg a month—once they finish.
The Reason for the Rapid Regain
Nutrition scientists believe the way of the jabs is key to understanding the accelerated weight return.
The injections copy a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of the hormone levels several times higher than the body's typical production might result in the body to produce less of its own natural GLP-1, and could diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this medication results in hunger is unsuppressed, making overeating a significant risk."
An Ongoing Disease?
Medical guidelines advise the jabs for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
A number of clinicians contend that, due to the high risk of relapse, the treatment might need to be ongoing.
This opinion is reinforced by pharmaceutical companies, who state that the findings "underscore the long-term nature of excess weight," akin to managing conditions like diabetes.
User Accounts
Users who have stopped the jabs describe a intense return of cravings.
"I experienced something activating and I was suddenly extremely hungry," said an individual.
The struggle is worsened if individuals have not adopted lasting dietary or behavioural modifications during therapy.
Widespread Interest
Survey data suggest that millions of people in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Adoption is more common among women than males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
Ultimately, clinicians emphasize that while the jabs are potent tools for weight loss, they are not a magic fix and maintained weight loss likely depends on combined behavioural support.
